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SUMMARY
A temperature sensitive (ts) mutant of feline calicivirus 
(FCV) was isolated from a vaccine strain of FCV. Virus-infected 
feline embryo cells were treated with the mutagen 5-fluorouracil 
(5-FU). The resulting virus was cloned and 192 clones were tested 
for growth at 31°C (permissive temperature) and 37°C 
(non-permissive temperature). Twelve clones which appeared to grow 
at 31°C but not at 37°C were selected and one clone was isolated, 
the growth of which was 760-fold lower at 37°C than at 31°C. This 
virus was designated FCV-ts.
The characteristics of growth of the mutant were examined. 
The growth of the virus at 31°C was prolonged compared to wild type 
FCV at 37°C with an eclipse period of 10 hours and maximum yield of 
virus was at 20 hours, compared to 2 hours and 3 hours respectively 
for wild type FCV.
The nature of the lesion was investigated. The virus
particles were not inactivated faster at 37°C than at 31°C over an 
incubation period of 6 hours. Virus adsorption to cells during 2 
hours was as efficient at 37®C as at 31°C. Temperature sensitivity 
was found, however, when the temperature of incubation was shifted 
from 31 °C to 37 ®C after only 2 hours of incubation following 
adsorption. These results suggested that the virus capsid protein 
might not be thermolabile but that an early event in viral growth 
was affected.
RNA synthesis in FCV-ts infected cells was examined in the 
presence of actinomycin-D to inhibit cellular RNA production. A
4-fold decrease in RNA synthesis was found 24 hours after infection 
when the temperature was shifted from 31 ®C to 37®C for 2 hours. 
This result suggested that the lesion affected RNA synthesis or 
survival and might be in a viral RNA polymerase activity.
The usefulness of FCV-ts as a vaccine in cats was 
investigated. Four kittens were given 1 x 106 plaque forming units
Vi
intranasally and examined at intervals for the presence of FCV in 
the oropharynx. Virus was isolated over a period of 26 days which 
compared to 40 days for the original FCV vaccine virus found in an 
earlier experiment. The reason for the prolonged growth might be 
that a revertant virus had arisen which grew well at 37°C. A clone 
of a revertant was subsequently isolated from one of the kittens 
which grew as well at 37°C as at 3I°C. Similar viruses were 
isolated when FCV-ts was passaged 3 times in cell culture. These 
results indicated that this particular ts mutant would offer no 
substantial advantage over the parental virus as a vaccine.
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ABBREVIATIONS
CPE Cytopathic effect
cpm Counts per minute
EDTA Ethylenediaminotetracetate
DFC-1 Dulbecco's modification of Eagle’s medium containing 1%
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GENERAL INTRODUCTION
1. Feline respiratory disease
Feline respiratory disease is a clinical syndrome that may be 
caused by one or several infectious agents so that it is similar in 
this respect to the common cold of humans or kennel cough of dogs 
(Arnett and Green, 1984). The infectious agents involved in feline 
respiratory disease include feline herpesvirus (FHV) and feline 
calicivirus (FCV) which have been reported to be responsible for up 
to 90% of infectious respiratory disease in cats (Ott, 1975). 
Infection with these viruses is discussed below in detail.
The remaining cases are caused by a variety of other agents. 
Feline reovirus type 3 has been isolated in the USA but the 
prevalence of the infection is unknown although it has been 
suggested that the virus is widespread in that country (Gillespie 
and Scott, 1973). This virus has been shown to cause a 
conjunctivitis and photophobia in experimentally infected cats.
Feline pneumonitis caused by Chlamydia psittaci was described 
in the USA by Baker (1944) but has not been shown to be of 
importance in the UK as a cause of respiratory disease (Povey and 
Johnson, 1971). However, the strain found in cats can cause 
conjunctivitis (Hoover et a l ., 1978).
Bacteria have been isolated from cases of respiratory disease 
in cats. For example, mycoplasma have been claimed to be involved 
particularly in conjunctivitis (Campbell et a l ., 1973; Tan and 
Miles, 1974). However, members of the mycoplasma group, including 
M.felis, M.gateae, M.feliminutum, M.arginini, M.acholeplasma and 
M.laidlawii have been isolated from the saliva of clinically 
healthy cats (Wilkinson, 1980). M.felis has also been isolated 
from the saliva of cats showing signs of conjunctivitis, which 
suggests a possible pathogenic role for the organism (Cole et al., 
1967).
Other bacteria acting alone or in various combinations may be 
secondary pathogens such as Streptococcus pyogenes. Staphylococcus
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aureus, Pasteurella multoclda, Bordetella bronchiseptlca and
Escherichia coll (Povey and Wilson, 1971; Powey, 1976).
2. Feline viral rhinotracheitis
Feline viral rhinotracheitis (FVR) was first described by
Crandell and Maurer (1958). Subsequent experimental studies were 
carried out by Johnson and Thomas (1966) and Povey and Johnson
(1967) which characterised feline herpesvirus type 1 as a species- 
specific member of the herpesviruses group sharing many biological 
and physicochemical properties with other members of that family 
(Crandell, 1973; Mekercher, 1973) Thus, there is only one
serotype of the virus. Also FHV was found to be of reasonably
uniform pathogenicity in susceptible cats (Crandell et al. , 1961, 
1973; Gaskell and Wardley, 1978). The virus is stable at pH 
between 6 and 7, at which it remains infectious for 5 months. It 
is heat-labile and sensitive to both ether and chloroform and is 
readily destroyed by many commonly used commercial disinfectants 
(Povey and Johnson, 1970; Scott, 1980). The virus grows readily in 
feline cell cultures in which it produces a characteristic slow, 
local cytopathic effect with intranuclear inclusion bodies in 
infected cells (Paul and Pratt, 1983). The virus forms plaques in 
cell culture. FHV is labile, surviving for only a few hours 
outside the cat (Povey and Johnson, 1970) and depends on direct or 
close contact of animals for transmission (Gaskell and Povey, 
1982).
Clinically, FVR can present a varied picture depending on 
levels of immunity, age and general health of the cat. Young 
kittens are most severely affected. There is often a febrile 
response and ocular involvement with conjunctivitis. In the second 
stage of the disease ocular and nasal discharges are copious and 
often become purulent signifying increased bacterial activity and 
an inflammatory response. Coughing may be a dramatic feature. 
Also FHV has been associated with skin ulcers although it was not 
determined whether the virus acted as the primary pathogen or as a 
secondary invader (Flecknell et a l ., 1979; Bistner et a l ., 1971).
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The incubation period may be as short as 2 days or as long as 
10 days (Crandell, 1973), the difference being related mainly to 
infecting dose of virus. The acute stage of the disease lasts for 
2 to 3 weeks when recovery occurs.
3. Feline calicivirus disease
Feline calicivirus disease (FCD) is of even more frequent 
occurrence although generally less severe than FVR. FCD is common 
in all cat populations and the severity of the condition varies 
with pathogenicity of the infecting strain of virus. In kittens 
between 3 and 12 weeks of age the disease is more severe and 
frequently fatal due to extensive pneumonia (Love and Baker,
1972). This is thought to correlate with declining levels of 
maternal immunity (Kahn and Gillespie, 1971). In contrast, in 
mature cats FCV infection may be subclinical or seen as a mild 
disease of the upper respiratory tract and oral cavity (Povey, 
1976).
Pathology and clinical signs
Clinical signs may be quite variable depending upon the strain 
of calicivirus involved, route of exposure, severity of the 
exposure and resistance of the exposed cat. FCV isolates generally 
can be grouped into 3 types, based on their virulence although it 
is often difficult to draw clear lines of distinction. An 
avirulent strain was found to produce no significant changes (Ott, 
1964). Calicivirus of moderate virulence produce ulcers of the 
tongue, hard palate and nostrils in exposed cats. FCV of high 
virulence produce pneumonic signs, with or without oral and nasal 
ulcers (Ott, 1983). Ulcers of the tongue, hard palate, and nose 
are more commonly seen with FCV, although they may also be caused 
by FHV as well (Arnett and Green, 1984). Some strains of FCV can 
cause gingivitis without other signs of respiratory disease 
(Gruffydd-Jones, 1985).
Different plaque types of FCV were shown to vary in their 
virulence and hence, the disease conditions they cause. Ormerod
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(1979) found that an extra-large plaque FCV strain was more
virulent than a minute plaque strain and that the lesions it caused
were more extensive. All of these observations suggested that FCV 
isolates of varying degrees of virulence cause a range of disease 
states in cats ranging from mild lesions of the oral mucosa and 
upper respiratory passages to quite marked cell destruction in the 
epithelial of the tongue and buccal cavity and in the interstitial 
tissue of the lungs (Hoover and Kahn, 1975; Povey, 1976; Holzing 
and Kahn, 1970; Povey and Hale, 1974).
The major clinical features of the disease caused by highly
virulent strains of FCV are fever, anorexia, depression, dyspnoea 
and death (Kahn and Gillespie, 1971). The disease is first
manifested as fever (104-105®F) and anorexia. The fever may 
fluctuate after the initial elevation but the temperature tends to 
remain elevated through the course of the disease. Depression is 
often marked. Death may occur within 5 days of the onset of signs. 
Recently Pedersen et al. (1983) described a transient syndrome of
fever, generalised stiffness and hyperaesthesia and pain on 
manipulation of joints caused by certain strains of FCV,
FCV has a greater predisposition for the lower respiratory 
tract and lung than other agents associated with feline respiratory 
disease, and oculonasal discharge in less frequent with FCV than 
with FHV infections (Povey and Hale, 1974) although in some cases 
sneezing and nasal ocular discharges may make it impossible to 
differentiate calicivirus infection clinically from FVR. (Cats 
with respiratory signs may be concurrently infected with FHV and 
FCV).
The diagnosis of FCV infection is based on the typical 
clinical signs of oral and occasionally nasal ulceration, with or 
without pneumonic signs. Virus isolation and identification of a 
calicivirus from lung tissue of a kitten that has died of a severe 
pneumonic disease is important in establishing the diagnosis of 
calicivirus infection in a cattery. However, isolation of 
calicivirus from the mouth of a cat without clinical signs of
infection is of less diagnostic significance, since it is 
impossible to be sure that the virus isolated is pathogenic.
Carrier states
Animals surviving the initial FCV or FHV attack usually turn 
into carriers. Such cats are known to play an important 
epidemiological role in outbreaks of severe FCV disease in kittens 
and breeding catteries (Love and Baker, 1972). Surveys have shown 
as high as 40% of animals to be viral carriers in colonies where 
FCV is endemic (Wardley et al., 1974) and even more (up to 80%) of 
cats which recover from FHV infection remain as viral carriers 
(Gaskell and Povey, 1973, 1977).
The carrier state of FCV is characterised by more or less 
continuous shedding of virus from the oropharynx for a period of 
weeks, months or even years (Povey et al., 1973; Wardley, 1977; 
Wardley and Povey, 1977). Viral shedding has been reported for
long periods from the tonsil (Almeida, 1968), faeces and urine 
(Rich and Fabricant, 1969; Povey and Hale, 1974; Stein, 1980), as 
well as nasal or conjunctival secretions (Povey, 1976).
Although FCV shedding from high level excretor carriers was
shown by many workers to be continuous, it is episodic with FHV, 
usually following natural stress due to re-housing, pregnancy, 
lactation and cat shows or artificially after corticosteroid 
treatment (Gaskell and Povey, 1973; 1977; Ellis, 1981). The site 
of FHV latency in carrier animals is not known, though there is 
some evidence that nervous tissue may be involved (Gaskell and
Povey, 1979).
Transmission
Carrier cats are considered to be a major source for
transmitting the infection. Natural transmission by these cats 
takes place through licking.
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Wardley and Povey (1977) suggested many factors which affect 
the transmission of FCV similar to those shown by Gaskell and Povey 
(1979; 1982) concerning FHV. These authors found a relationship
between the level of infecting dose and the length of the 
incubation period as well as the severity of the resulting 
syndrome. They also showed that the duration of contact plays a 
role in transmitting the disease. Povey and Ingersoll (1975) 
showed that FCV was readily transmitted to cats in close contact as 
well as indirectly on the hands of attendants. The distance 
between infected and susceptible cats was found to be of critical 
importance in transmitting the disease. As it is not likely to 
have virus-containing microdroplets sneezed by infected cats 
spreading beyond 4 feet, it was necessary for a successful airborne 
viral transmission to have the infected and susceptible cats within 
this range (Wardley and Povey, 1977).
The age of disease establishment in newborn kittens was shown 
to vary depending on the level of maternal immunity and to the 
amount of virus to which these kittens are exposed. Kittens 
exposed to high level excretors would pick up infection and succumb 
earlier (Johnson and Povey, 1984).
Little is known of the interaction between FCV and maternally 
immune kittens during the period of declining passive immunity 
(Johnson and Povey, 1984). Maternal antibody which persists for 
approximately 13 weeks (Povey, 1970; Johnson and Povey, 1983) 
appears to provide incomplete protection against FCV infection 
(Gillespie and Scott, 1973). Kahn and Gillespie (1971) observed 
that weanling kittens with low titres of virus neutralising 
antibody to FCV were susceptible to experimental aerosol challenge 
with a virulent strain but the mortality rate was lower than in 
seronegative kittens. However, signs of FCD have been shown in
6-day old kittens born to a seropositive, apparently uninfected dam 
(Kahn and Walton, 1971). Gaskell and Wardley (1978) have suggested 
that many kittens under conditions of natural exposure experience 
subclinical and immunising infections. Johnson and Povey (1984) 
studied the clinical, virological and immunological events
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occurring in kittens born to FCV carrier queens and found that all 
the kittens became infected between 3 and 4 weeks after birth and 
shed FCV consistently for periods of 3 to 11 weeks.
The persistence of maternally derived antibody is dependent 
upon the amount of antibody acquired from the mother and the rate 
of catabolism of immunoglobulins in offspring (Brambell, 1970). 
The estimated half-life of 15 days for maternal FCV antibody agrees 
with reports on maternal antibody to feline leukaemia virus
(Jarrett et al., 1977) and FHV (Gaskell, 1975) but is greater than 
the 9.5 day half life determined for maternal antibody to feline 
panleukopenia virus (Scott et a l ., 1970). It appears, however, 
that this balanced host-virus interaction during the transition 
from passive to active immunity is sensitive to factors such as 
virus dose and the limited nature of protection afforded by 
maternal immunity. Ormerod et a l . (1979) suggested that the extent 
of experimental infection not only depends on virus dose but also 
on the route of administration. For example aerosol dosage
favoured deposition of virus in lungs, an important event in the 
development of pneumonic FCV infection, while nasal installation 
tended to produce oral and nasal lesions only.
4. Isolation of FCV
Fastier (1957) in New Zealand was the first to isolate FCV. 
In the same year Bolin (1957) also isolated the virus in the USA. 
Other workers have recovered the virus from cats in different parts
of the world: USA (Sinha, 1957; Bittle et al., 1960; Crandell and
Madin, 1960; Kahn and Gillespie, 1970), Switzerland (Biirki, 1963), 
Italy (Torlone, 1960), England (Prydie, 1966; Povey, 1969), 
Australia (Studdert et al., 1970) and Scotland (Ormerod and 
Jarrett, 1978). The virus has been isolated from cases of disease, 
convalescent carriers (Gillespie and Scott, 1973) or from the 
oropharynx of clinically healthy cats (Piercy and Prydie, 1963; 
Biirki, 1971; Walton and Gillespie, 1970; Povey and Johnson, 1971; 
Wardley et a l ., 1974; Ellis, 1981). Wardley et al. (1974) found 
the prevalence of FCV to be 8% of normal household pet cats, 24% of
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cats at shows and 41.5% of cats in multicat households.
The virus has been isolated in monolayer cultures of feline 
kidney cells (Crandell, 1960; Fastier, 1957), diploid feline tongue 
and feline thymus cell lines (Lee, et al. , 1969) cell lines from 
embryonic feline lung (Crandell, et a l ., i960). FCV has a rapid 
cytopathic effect that tends to distinguish it from FHV which 
induces a slower focal cytopathic effect and also produces 
inclusion bodies in cell culture. Cell cultures of heterologous 
species usually do not support replication of FCV and the virus 
does not propagate in embryonated hens' eggs or in common 
laboratory animals.
5. Characteristics of calicivirus
FCV belongs to the family Caliciviridae (Studdert, 1978; 
Schaffer, 1979; Schaffer et al. , 1980). Caliciviruses were first 
recognised in 1932 when they were shown to cause vesicular 
exanthema of swine in Southern California (Traum, 1936). Other 
caliciviruses, of which the prototype is San Miguel sealion virus, 
were isolated from pinnipeds in California with ulcerative lesions 
of the mouth (Smith et a l ., 1973). More recently caliciviruses 
have been isolated from fish in the Pacific Ocean (Smith et al. , 
1981). It has been suggested that both vesicular exanthema and San 
Miguel sealion virus are caliciviruses of fish which have spread 
through the food chain to sealions, seals and pigs.
Other caliciviruses have been isolated from calves, a rock 
rattlesnake, walrus and dolphins, (Smith et al. , 1983b) and from 
pygmy chimpanzee (Pan paniscus) (Smith et al., 1983a). There are 
probably at least three human serotypes which will not grow in 
foetal kitten cells and recently a human candidate calicivirus was 
described which replicates in human embryo kidney cells (Cubitt and 
Barrett, 1984). Particles resembling calicivirus have also been 
detected in faeces of children showing no clinical symptoms 
(Madley and Cosgrove, 1976; Flewett and Davis, 1976). Similar 
viruses were implicated in outbreaks of vomiting and diarrhoea in 
England and Japan in which many school children as well as adults
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were involved in small epidemic outbreaks (Sellers, 1984),
FCV was originally assigned to the family picornaviridae like 
all the other members of the genus because of their resemblance to 
picornaviruses: for example, small size, ether and chloroform
resistance, virions composed of a single-stranded, non-segmented 
RNA and replication in the cellular cytoplasm. However, there are 
some clear differences. Thus, their virion is larger with a 
diameter of 35 to 40 nm, and their capsid is composed of a single 
major polypeptide (Bachrach and Hess, 1973) with 32 cup-shaped 
depressions arranged in icosahedral symmetry (Studdert, 1978;
Schaffer, 1979; Hagan and Bruners, 1981).
6. Structure and properties of FCV
The virion of FCV is non-enveloped (Fastier, 1957; 
Bartholemew, 1968), icosahedral in shape, contains linear
(non-segmented) single-stranded RNA (Adldinger et al. , 1969; Khan, 
1969) and protein (Wawrzkiewicz et al., 1968; Newman et al., 1973; 
Bachrach and Hess, 1973). The RNA forms 18% of the virion mass 
with a molecular weight of 2.8 x 10^ and the protein comprises 80% 
with a molecular weight of 12.4 x 10^ so that the total virion mass 
is 15.2 X 10^ daltons (Burroughs et al., 1978). The virus particle 
size has been determined by filtration (Biirki, 1965; Crandell, 
1967) and electron-microscopic examination (Zwillenberg and Biirki, 
1966; Almeida, 1968; Strandberg, 1968). The virus has a diameter 
of 35-40 nm (Zwillenberg and Biirki, 1966; Almeida et al., 1968) and 
the surface resembles a Star of David made from two interlocking
equilateral triangles with a central hole (Madley, 1979). The
pattern of the holes or depressions suggests a 32 subunit 
structure. In negatively stained preparations, the capsid shows a 
number of large, dark stain penetrated cup-shaped structures 
(Zwillenberg and Biirki, 1966; Almeida et a l , 1968). Strandberg
(1968) described the capsomers as thin and rod-like 5 nm long and 
2-5 nm wide.
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Physlochemical properties
FCV has a buoyant density of 1.36 - 1.39 g/cm^ in caesium 
chloride (Studdert et al., 1970; Newman et a l ., 1973) and the 
sedimentation coefficient is 160-170S. The virus is resistant to 
lipid solvents such as ether or chloroform (Biirki, 1966; 
Bartholemew and Gillespie, 1968) and also to hydroxybenzylbenzi- 
midazole, guanidine hydrochloride and 0.2 per cent sodium 
deoxycholate (Biirki, 1965). FCV is labile at pH 3 but not at pH 7 
(Oglesby et al., 1971) and is readily inactivated at 50°C in the 
presence of Ca^^ or Mg'*"*' (Khan and Gillespie, 1970). The virus is 
known to retain its infectivity at low temperature (-65°C) for at 
least 4 years (Gillespie and Scott, 1973; Holmes and Gillespie,
1973). Among different temperatures for storing purified FCV 
Komolafe (1979) found that 4°C was better than -70°C for retention 
of infectivity.
No haemagglutinin has been associated with FCV (Crandell et 
al., 1960; Gillespie et al., 1971).
FCV produces plaques in cell cultures overlayed with agar, 
agarose or methyl cellulose (Biirki, 1965; Crandell, 1967; 
Bartholemew, 1968; Ormerod and Jarrett, 1978). There is a 
correlation between plaque size and virulence, large plaque strains 
being more pathogenic than minute plaque strains. (Ormerod and 
Jarrett, 1978).
The virus replicates in the cytoplasm of infected cells, and
is observed as single particles, extensive single particles,
non-regular accumulations as paracrystaline arrays or a single or 
multiple linear arrays associated with microfibrils (Strandberg, 
1968; Studdert and Oshea, 1975; Ormerod and Jarrett, 1978).
7. Proteins of FCV
Black and Brown (1977) identified two polypeptides in infected
cells with molecular weights of 100 x 10^ (plOO) and 80 x 10^ (p80)
1 1
which had no relationship to the major capsid protein of molecular 
weight 68,000 (p68) isolated from the virus. Komolafe (1980) 
confirmed the presence of p80 and p68 but not plOO in FCV infected 
cells, and reported the presence of two other apparently 
virus-specific polypeptides of molecular weights 80,000 and 40,000.
In an infected cell the virus-specific proteins and nucleic 
acid are synthesized separately and consequently must be brought 
together and assembled into mature viral particles. The mechanism 
of assembly of these particles from progeny RNA and protein is not 
known with any certainty and ]<»tle work has yet been done on FCV 
in this direction. Komolafe et a l . (1978) described a protein
subunit of the virus with a sedimentation coefficient of 15S which 
was generated when purified virus was disrupted at low pH. A 
component with identical physical characteristics to this subunit 
was produced in cells infected with FCV and was apparently a 
precursor in the assembly of the viral capsid.
8. Antigenic properties of feline caliciviruses
Investigation of the antigenicity of FCV has been carried out 
by many workers (Bittle et al., 1960; Bürki, 1965; Crandell, 1967; 
Prydie, 1966; Povey, 1971; Parker, 1972; Studdert eé a l ., 1970; 
Povey, 1974 and Povey and Ingersoll, 1975). Results based on the 
use of the neutralisation test which is most widely used for 
serotype identification, showed considerable serological 
differences between isolates but with much cross- reaction. These 
results were further confirmed by the use of complement fixation 
tests (Tan, 1970; Gillepsie and Scott, 1973) and immunodiffusion 
(Tan and Miles, 1971; Gillespie and Scott, 1973). Gillespie et 
a l . (1971) in a study on FCV-infected feline cells in culture by 
immunofluorescence showed that there was cross-reactivity between 
strains. Finally, Povey (1974) studied the serological
relationships among a total of 46 strains of FCV isolates by serum 
neutralisation and found that all isolates tested could be regarded 
as serological variants of a single serotype. Using an arbitrary 
20 antibody-units concept as is used in human rhinovirus serology
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(Kapikian et a l ., 1967), hè concluded that no isolate could be 
distinguished as a separate serotype.
Komolafe (1978) described 2 surface antigenic determinants of 
FCV. These were suggested to be group-specific and strain-specific 
determinants, one of which was responsible for the production of 
neutralising antibodies found in their homologous immune sera.
9. Vaccination against feline viral respiratory disease
As described above, FHV and FCV constitute the major cases of 
respiratory disease in cats. Several vaccines are available for 
protection against both of these diseases which contain either 
individual viruses or are a combination of both viruses, sometimes 
with feline panleukopenia virus. These forms include inactivated 
virus which is injectable and modified live virus products which 
are available for injection or for intransal instillation.
In the UK the first of several vaccines against FVR and FCD
became commercially available in 1976. Table 1.1 is a summary of
the vaccines currently available in the UK.
Isolation of the FVR virus and cross-immunizing with FCV 
strains (Kalunda, 1975; Povey, 1979) eventually led to the 
development of vaccines for prevention of both diseases. The 
original vaccines contained modified live viruses and were given 
intramuscularly or subcutaneously. Later studies indicated,
however, that intranasal administration of FHV and FCV antigens 
might be more effective. Kahn et a l . (1975) obtained distinctly
better protection using a single intranasal dose of the F-9 strain 
of FCV which was already known to be broadly antigenic and of low 
virulence (Kalunda et al., 1975). This virus was also used .n 
several other vaccine preparations either singly (Bittle and Rubi_, 
1976) or in combination with attentuated FHV and attenuated or 
inactivated panleukopaenia virus vaccine (Bittle and Ruble, 1975; 
Davis and Beckenbauer, 1976).
TABLE 1 Vaccines currently available in the UK for the
protection of cats against viral respiratory disease
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Trade
name
Manu­
facturer
Disease Vaccine 
covered type
Vaccine
route
Dosage
regime
Booster
vaccin­
ation
Feliflu
FVR-C
C-Vet FVR
FCD
modified
live
sc or 
im
2 doses 
3-4 weeks 
apart
1 dose 
annually
Felocell
CVR
Smith Kline FVR
FCD
modified
live
sc or 
im
2 doses 
3-4 weeks 
apart
1 dose 
annually
Katavac
CH
Duphar
Veterinary
FVR
FCD
modified
live
in 1 dose 1 dose 
annually
Nobi-vac
Tricat
Intervet FVR
FCD
FP
modified
live
sc or 
im
2 doses 
3-4 weeks 
apart
1 dose 
annually
Purtect
RC
Glaxovet FVR
FCD
modified
live
sc 2 doses 1 dose 
not less annually 
than 3 
weeks apart
Purtect
RCkP
Glaxovet FVR
FCD
FP
modified
live
sc 2 doses 1 dose 
not less annually 
than 3 
weeks apart
Vaxicat
Plus
Coopers
Animal
Health
FCD
FP
inactivated sc 
oil adjuvanted
2 doses 
3-4 weeks 
apart
1 dos 
annually
FVR = Feline viral rhinotracheitis 
FCD = Feline calicivirus disease 
FP = Feline panleucopenia
sc = subcutaneously 
im = intramuscularly 
in = intranasal
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In North America, Povey and Wilson (1978) developed a combined 
FHV and FCV inactivated vaccine and concluded that protection 
afforded against challenge, was comparable to that achieved by 
modified live virus vaccines. In the UK there is one killed feline 
respiratory virus vaccine available.
Some evidence was found in an earlier study that previously 
unexposed cats vaccinated intramuscularly with a combined live 
attenuated vaccine against FCV infection and FHV could subsequently 
become carriers of FHV following challenge and subclinical 
infection with a field isolate of the virus (Orr et a l ., 1978). 
Virus isolated from one such carrier animal was found to be 
virulent and such animals would clearly be of epidemiological 
importance. These findings contrasted with the intranasally 
administered combined live modified vaccine with which there 
appeared to be evidence for the development of an FHV carrier state 
following challenge.
Gaskell et a l . (1982) in a study on cats vaccinated intra­
muscularly with a combined inactivated FCV, FHV and feline 
panleucopenia vaccine (Vaxicat Plus; Tasman Ltd) found that no 
clinical signs appeared following vaccination and there was no 
evidence of local reaction or of viral shedding following 
vaccination compared with that shown for other FCV vaccines.
The intramuscular attentuated virus vaccines have the 
advantage of not producing clinical signs or viral shedding at the 
time of vaccination (Bittle and Rubic, 1974; 1975) compared with 
intranasal attenuated virus vaccines which not uncommonly produce 
mild clinical signs in the first week following vaccination. Thus, 
mild sneezing may be observed 5-9 days later in up to 60 per cent 
of cats and some ocular and nasal discharge, and oral and na al 
ulceration have been reported (Davis and Beckenbauer, 1977; Pov /, 
1977; Povey and Wilson, 1978; Wilson, 1978; Orr et a l ., 1980). 
Although intranasal vaccine virus replicates locally and therefore 
may spread to in-contact animals, no evidence of disease in such 
animals has been reported in the UK (Gaskell, 1981). In North
I J
America mild signs have been reported with in-contact cats 
following the use of intranasal vaccine (Kahn, 1977).
Bittle and Rubic (1975; 1976), Kahn and Hoover (1976) and Orr 
et a l . (1978) found that no shedding of virus or spread to 
in-contact cats occurred in intramuscularly vaccinated cats and 
therefore vaccination by this route usually appears to be free from 
any adverse effects. However, Cox (1978), North (1978) and 
Robinson (1978) suggested that the disease may appear in endemic 
colonies following vaccination.
The modified FHV in the intranasal vaccine may be shed by the 
vaccinated cat for up to 16 days after vaccination and may spread 
to susceptible cats closely associated with the vaccinated cats 
(Orr et a l . , 1980). However, calicivirus in a combined intranasal 
vaccine may be shed for 3-83 days post vaccination (Orr et al. ,
1980). Povey and Wilson (1978) reported in their study that cats
vaccinated with inactivated vaccine and challenged appeared to 
become FCV carriers and then infect susceptible in-contact 
animals. The reason why vaccination by the intramuscularly route 
appears to protect against infection is not clear, though it may be 
related to differences in local immunity and the ability of the 
challenge virus to survive and replicate (Gaskell, 1981).
Following intranasal vaccination both viruses replicate 
locally and are shed in the oropharynx (Orr et a l ., 1980). Locally 
replicating virus probably stimulates a better immunity at the 
actual site of infection than does systemically administered 
virus. Intranasal vaccines stimulate local resistance to both
viruses within 24 hours (York and Slater, 1976) or 48 hours after a 
single vaccination (Davis and Beckenbauer, 1977; Folkers and
Hoogenboon, 1978) compared with intramuscular vaccines which need a 
longer time to establish protective immunity. These vaccines 
produce a humoral antibody response within 14 days compared with 7 
days for the intranasal vaccine. Scott (1977) suggested that 
intranasal vaccine stimulates a rapid localized as well as a 
systemic humoral immune response. These suggestions have led to
0the recommendation of the intranasal vaccination to stimulate rapid 
immunity in outbreaks of disease in catteries and in chronically or 
recurrently diseased cats. McDermott and Bienenstock (1979) and 
Povey (1977) concluded that the intranasal route gives more 
complete protection but at the expense of post-vaccination 
complications which can be severe.
It is probably true that intranasal vaccination gives better 
protection than intramuscular vaccination, though few challenge 
studies with the modified live intranasal vaccine (Katavac CH, 
Duphar Veterinary Ltd) currently available in the UK have been 
published. Orr et a l . (1980) suggested that vaccination via the 
intranasal route, however, may prevent the subsequent development 
of an FHV carrier state following challenge with virulent field 
virus, at least in the short term. FHV was recovered for up to 
only 13 days following vaccination and attempts to stimulate
shedding of any latent virus with a corticosteroid course 58 days 
after vaccination were unsuccessful. The FHV vaccine strain used 
in this work was a temperature sensitive mutant (Slater and York, 
1976) and it may be that by confining replication of the virus to 
the lower temperature of the nasal chamber, no carrier state can 
develop. The site of FHV latency in carrier cats is not known, 
though there is some evidence that the nervous tissue may be
involved (Gaskell and Povey, 1979). Levels of serum neutralising 
antibody are currently used for determining efficacy though the 
level of protection is almost certainly related to other components 
of the immune response as well.
Immunity to FHV and FCV following vaccination may last up to a 
year (Bittle and Rubic, 1974). Orr et a l . (1980) found that 11
weeks after vaccination, protection was complete in all 8
vaccinated and challenged cats, whereas all 4 unvaccinated and 
challenged controls showd severe signs characteristic of FVR.
Vaccine efficacy and recommendation for the age of initial 
vaccination in young kittens depends on the rate of maternal 
antibody decay. However, vaccination programmes for the
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preventation of FVR of cats usually commence at 9 to 12 weeks of 
age since kittens that have obtained colostrum from immune mothers 
can have FHV antibody for up to 10 weeks although only approx­
imately 50% of them have minimal or non-detectable amounts of serum 
neutralising antibody by 6 weeks of age (Povey and Johnson, 1970; 
Edwards et a l ., 1977).
Recent studies have successfully introduced an intra­
muscularly, killed virus adjuvanted vaccine against FHV which 
operates in the presence of maternal antibody. Johnson and Povey 
(1985) indicated that early vaccination is potentially useful in 
the control of FVR in kittens in catteries in which respiratory 
tract disease develop before the recommended vaccination age of 
9-12 weeks. With the live intranasal vaccine results were 
consistent with earlier studies (Slater and York 1976; Ott, 1978; 
Pickering, 1981) which provided evidence that protection could be 
achieved in kittens even during the presence of maternal antibody. 
However, in the recent study, multiple vaccine doses were found 
unnecessary. Thus it may be particularly useful for the protection 
of young kittens in catteries where the disease is endemic.
All these factors make it important that a combination of 
management and vaccination is employed in the control of FCV and 
FHV infections (Gaskell and Wardley, 1978). Cats should be 
vaccinated annually and should be separated as far as possible from 
contact with the virus (Gaskell and Wardley, 1978). Animals at 
particular risk should be boosted 6-monthly. In breeding colonies 
where the disease is endemic breeding queens should be regularly 
vaccinated and their immunity boosted before mating with an 
inactivated vaccine. Kittens should be vaccinated as soon as 
maternal antibodies are at a non-interfering level and certainly 
before exposure to adult stock (Gaskell, 1981).
10. Aims of the present study
The major aim of this study was to isolate a mutant of FCV 
which might be useful as a vaccine against FCV infection in cats.
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The efficacy of a mutant of FHV has been impressive in
controlling FVR, This virus grows for only a short period in the 
upper respiratory tract and so the possibility of spread of vaccine 
virus to other cats is limited. However current attenuated FCV
vaccine virus given intranasally grows for periods of up to 40 days 
and can be transmitted to in-contact cats (0. Jarrett, personal 
communication). A mutant of FCV might solve this problem.
Another reason for wishing to isolate mutants was to
examine the genetic composition of FCV. Only one gene product, the 
capsid protein, has been unequivocally identified. Mutants might 
help to identify other gene products such as an RNA polymerase and 
open the way for a genetic analysis of caliciviruses. i
In this thesis Chapter 1 gives the general materials and
methods which were used. Chapter 2 describes the isolation of a ^  
mutant of FCV. Chapter 3 contains details of the growth cycle of 
this mutant. In Chapter 4, experiments to characterise the mutant 
are described and in Chapter 5 evidence is presented that the 
lesion might be in the viral RNA polymerase. Chapter 6 is an
account of the intranasal administration of the ^  mutant to cats 
and the isolation from one of these animals, and from mutant virus 
grown in cell culture, of a revertant virus.
CHAPTER 1
GENERAL MATERIALS AND METHODS
Derivation of FCV-K
FCV-K was derived by 0. Jarrett from a vial of Katavac-CH 
vaccine (Duphar Ltd.) which contained FCV and FHV components. The 
freeze-dried vaccine was reconstituted with sterile diluent and 
removed from the vial into a 5 ml glass bottle. In order to 
inactivate the herpesvirus a volume of 0.5 ml vaccine was mixed 
with an equal volume of chloroform and was shaken for 5 minutes. 
The mixture was poured into a glass conical centrifuge tube and 
spun at 2000 rpm for 10 minutes. The aqueous phase was removed, 
dispensed in 3 0.1 ml lots and frozen at -70*C. One aliquot was
thawed and tenfold dilutions were made in medium. One ml of each 
dilution was inoculated into a confluent FEA monolayer in 5 cm 
plates. After 3 days there was extensive cytopathic effect (CPE) 
in all dilutions down to lO"”^. The medium from the plate 
inoculated with the lO"^ dilution was harvested, centrifuged at 
2000 rpm for 10 minutes and the supernatant fluid was removed and 
stored in 0.5 ml lots at -70°C.
Cells
Feline embryo cells of the FEA strain (Jarrett et a l ., 1973) 
were used between passage numbers 10 and 80.
Media
Dulbecco's modification of Eagle’s Minimal Essential Medium 
(Gibco, Ltd) was used to grow the FEA cells. Growth medium was 
enriched with 10% foetal calf serum (FCS) (Imperial Laboratories) 
(DFC-10). Maintenance medium contained 1% FCS (DFC-1).
Agarose overlay medium
A stock solution of 4% agarose was prepared by dissolving 20 
gm of agarose powder (LMT Seaplaque, Miles Laboratories) in 500 ml 
of deionised water in an autoclave at 15 lbs/in^ pressure for 15 
minutes. The solution was dispensed in 25 ml volumes and
re—autoclaved at 15 Ibs/ln^ pressure for 13 minutes. Agarose was 
added to the overlay medium to a final concentration of 1%. To 
prepare this, 25 ml of stock 4% agarose was melted in a microwave 
oven then cooled to 42°C or 37®C in a water bath. This solution 
was then mixed with 75 ml of Dulbecco’s MEM in which the water 
content had been reduced by one-third.
Cell cultures
FEA cells were grown in 2.5 litre rotating bottles containing 
100 ml of DFC-10 and were maintained at 37®C. Cells were 
subcultured 1:3 at weekly intervals. Monolayers were detached by 
removing the growth medium and rinsing the cells first with 20 ml 
of 0.02% EDTA in PBS followed by 25 ml 0.01% trypsin in 0.02% 
EDTA. The cells were resuspended in DFC-10, then transferred into 
fresh bottles which were flushed with 5% CO2 in air and returned to 
37®C.
Plaque assays
Plaque assays were carried out in either 5 cm polystyrene 
plates (Nunclon Delta) with 4 ml DFC-10 or in 12-well cluster 
plates (Costar) with 2 ml DFC-10 in each well. The 5 cm plates 
were seeded with 2 x 10^ cells and 12-well plates with 1 x 10^ 
cells in each well. After 24 hours' incubation at 37®C, these 
plates were infected with a volume of 1 ml virus per 5 cm plate or 
0.5 ml per well of a 12-well plate. After an adsorption period of 
1 hour, the inoculum were removed and the plates were washed twice 
with 2 ml DFC-1 medium. An agarose overlay was added to the plates 
which were then incubated for 2-3 days. The plates were fixed and 
stained by adding 2 ml (to 5 cm plates) or 0.5 ml (to cluster 
plates) of a solution of 0.5% crystal violet, 10% formaldehyde and 
5% methanol. The plates were incubated overnight at room 
temperature. The overlay was then washed off, the plates were 
washed in water, dried, and the plaques were counted.
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Introduction
Mutation is defined as the discontinuous event which results 
in a change in information content of a genome. This could arise 
in two ways: a point mutation which includes the substitution of
one base by another, and a frame-shift mutation which occurs by
insertion or deletion of single base pairs. This latter event is
more extensive because it alters the entire gene from the site of 
the change (Pringle, 1984). Mutation can happen spontaneously or 
artificially by using chemical or physical agents (mutagens). 
Spontaneous deletion mutation is common to all viral groups. These 
mutant viruses may interfere specifically in the process of
replication of normal genomes and may play a natural role in 
stimulating the immune system (Pringle, 1984).
In viruses with RNA genomes high rates of spontaneous mutation 
have been measured, in the order of 10"^ to 10“^ per incorporated 
nucleotide. For example, cloned populations of the paramyxovirus, 
Newcastle disease virus, contained small plaque mutants at a 
frequency of 3 to 7% (Granoff, 1961) and in the rhabdovirus, 
vesicular stomatitis virus, frequencies of 1 to 5% have been
reported for spontaneous mutation to the phenotype (Pringle,
1975). In contrast, the rates of spontaneous mutation are quite 
low in DNA genomes being as low as 10~® to 10“ ^^ per incorporated 
nucleotide. For example, less than 0.1% spontaneous mutants 
were reported for rabbitpox virus (Sambrook et a l ., 1966).
Artificial mutation can be induced by using mutagens. 
Mutagens are used to increase the frequency of mutants in the 
population that is subsequently screened by the use of appropriate 
selection pressures. A large number of different mutagens has been 
used in animal virus systems, but these fall into a small number of 
classes defined by the mechanism of mutagenesis (Drake, 1969, 1976; 
Freese, 1963). The base analogues 5-fluorouracil (5-FU) and 
5-azacytidine for RNA viruses, and 5-bromodeoxyuridine for DNA 
viruses, are incorporated into the viral genome and mutations are 
produced by miscoding during replication (Pringle, 1984). The
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major problem associated with the use of mutagens is selecting an 
appropriate dose so that the frequency of mutation with the desired 
phenotype is increased. Mutants are picked from the lowest mutagen 
dose giving as reasonable frequency of mutations with the desired 
phenotype (Ramig, 1985). Other mutagens induce mutation by direct 
chemical change. For example, heat inactivation mutation occurs 
when the mutants are unable to multiply in susceptible cells at 
high temperature but are unrestricted at low temperature.
The generation of mutants has been attempted by many workers 
for vaccine manufacture. Attempts have been made to develop 
mutants from feline respiratory viruses. An attentuated FHV has 
been reported by Bittle and Rubic (1975) and Slater and York 
(1976). Also Bearle (1971), Kim et a l . (1971) and Brown et al. 
(1975) found that it is possible to attenuate a virus without 
altering its antigenicity by propagation at low temperatures such 
as 26®C or 32°C. Bittle and Rubic (1976) attentuated the F9 strain 
of FCV after passage in cell culture at low temperature (30 or 
32®C) over 148 passages.
A  number of workers have used 5-FU to increase mutation. Such 
mutants of wild type strains of vesicular stomatitis virus have 
been isolated following mutagenesis (Pringle, 1970; Pringle et a l ., 
1971; Pringle and Wunner, 1973). Richmond (1975) and Richmond and 
Polatnick (1976) isolated a mutant of foot-and-mouth disease
virus mutagenized with 5-FU which produced plaques at the 
permissive temperature of 33®C but not at 38.5®C. Chanock and
Murphy (1980) used 5-FU to increase mutation rates and produced a 
series of mutants for experimental influenza and respiratory
syncytial virus vaccines. These have not gained acceptance, mainly 
because they have shown a tendency to revert to virulence.
Georgine et a l . (1976). Gadkari and Pringle (1980) also isolât ^ d 
ts mutants of respiratory syncytial virus. mutants have al o
been isolated from Bunyumwera virus (Iroegbu and Pringle, 1981) and 
Chandipura virus, a human rhabdovirus (Gadkari and Pringle, 1980) 
by treatment with 5-FU. Eastman and Blair (1985) isolated 10 
mutants of the togavirus, Japanese encephalitis virus, after
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mutagenesis by growth of wild-type virus in the presence of 5-FU or 
5—azacytidine. Mutants were selected which grew at least 100-fold 
better at 33®C than at 41°C. The 5-FU was found to be more 
effective at inducing t^ mutation than was 5-azacytidine.
A property associated with most mutation is the ability to 
revert to the wild type. Reversion can be induced by mutagens and 
often knowledge of the mechanism of the mutagen inducing the 
forward mutation along with that of the mutagen inducing reversion 
can allow deduction of the base change involved in the original 
mutation (Ray and Fields, 1979).
The aim of the work described in this chapter was to isolate 
ts mutants from a vaccine strain of (FCV-K) by using a low 
temperature (31°C) as the permissive temperature. A chemical agent 
(5— FU) was used in an attempt to increase the mutation rate.
Materials and Methods
5-fluorouracil (5-FU)
5-FU (Sigma) was used as a mutagen. A stock solution was 
prepared by dissolving 2 mg 5-FU in 10 ml distilled water to make a 
concentration of 200 yg/ml which was stored at 4®C.
Toxicity of 5-FU
Confluent FEA cell monolayers in 5 cm plates seeded with 2 x 
10^ cells and incubated for 24 hours at 37°C were used to determine
the toxicity of the 5-FU. Serial dilutions covering a range from
500 to 30 yg/ml of 5-FU were prepared in medium, then the inoculum 
was removed from the plates and a volume of 4 ml from each dilution
was added. These plates were incubated at 37®C for 24 hours and
examined for survival of the cells.
Growth of FCV-K in presence of 5-FU
Confluent monolayers in 5 cm plates were obtained by the 
incubation of 2 x 10^ FEA cells in 4 ml of DFC-10 for 24 hours at 
37®C. The incubation medium was removed and 1 ml of FCV-K stock 
(1.4 X 10^ pfu/ml) was added. The infected cells were incubated at 
37®C for 2 hours, then the inoculum was removed and the plates were 
washed twice with 2 ml of DFC-1. Serial dilutions covering a range 
from 500 to 30 yg/ml of 5-FU were prepared in medium and 4 ml from 
each dilution was added to a plate which was incubated at 3l°C
until a CPE was observed in virus-infected control plates not 
containing the mutagen. The culture fluids were then harvested and
centrifuged at 2,000 rpm for 10 minutes to remove cellular debris.
The supernatant fluid was collected and 1.0 ml volumes were
transferred to small screw-capped vials which were stored at -70°C 
for further use.
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Assay of virus treated with 5-FU
Confluent FEA cell monolayers in 12-well cluster plates were 
obtained by seeding with 1 x 10^ cells and Incubating for 24 hours 
at 37®C. The incubation medium was removed and ten-fold dilutions 
from each sample of 5-FU treated virus were added at 0.5 ml/well. 
The infected plates were incubated at 31*C for 2 hours to allow the 
virus to adsorb. The inocula were then removed and agarose overlay 
medium was added. Infected cultures were incubated for 3 days at 
31 ®C. The monolayers were then stained and the plaques were 
counted.
Isolation of FCV ts mutant virus
Forty confluent FEA cell monolayers in 5 cm plates were made 
by incubation of 2 x 10^ FEA cells per plate for 24 hours at 37®C. 
The medium was removed and a suitable dilution of FCV-K which had 
been grown in the presence of 200 yg/ml 5-FU, was made. One ml was 
inoculated into each plate and the infected plates were incubated 
at 31*C for 2 hours. The inoculum was removed and the plates were 
washed twice with medium. A volume of 4 ml agarose overlay medium 
was added and the infected cultures were incubated for 3 days at 
31® C.
Plates containing only 4-10 plaques were selected and suitable 
plaques were marked on the underside of the plate. A total of 192 
plaques were picked through the overlay using an automatic pipette 
(Gilson P200) set to take up 100 yl and each agarose plug was added 
to 100 yl DFC-10 medium in a 96-well flat-bottomed cell culture 
plate (NUNC) . A volume of 50 yl was then removed into a duplicate 
well on another plate. A volume of 50 yl DFC-1 containing 5 x 10^ 
FEA cells was added to each well. The plates were then incubated 
at 31®C or 37®C for 3 days. Clones demonstrating CPE at 31®C ’ it 
not at 37®C were identified as potential ^  mutants and wt _e 
collected and stored at -70®C. These samples were recultured in 5 
cm plates containing 2 x 106 -pEA cells with 4 ml DFC-10 then after 
3 days' incubation in 31®C the plates were harvested, transferred
to conical centrifuge tubes and spun at 2,000 rpm for 10 minutes. 
The supernatant fluids were transferred into screw-cap vials and 
stored at -70®C then tested for temperature sensitivity by plaque 
assay.
Plaque purification of mutant virus
Mutant virus clones were produced by plaque purification. FEA 
monolayers in 5 cm plates were incubated with terminal dilutions of 
virus. Adsorption for 2 hours was followed by removal of the 
inoculum and washing twice in DEC. An agarose overlay medium was 
applied. Plaques developed and could be visualised after 3 days' 
incubation at 3l*C. Plates containing only 5-10 plaques were 
selected and suitable plaques were marked on the underside of the 
plate. The plaques were transferred by using an automatic pipette 
into 5 cm plates containing FEA monolayers with 4 ml DFC-10. After 
3 days' incubation at 3l*C a CPE developed. The medium was 
removed, centrifuged at 2,000 rpm for 10 minutes and the
supernatnant fluid was filtered through a 0.22 ym Millipore filter 
to remove viral clumps. The suspension was then transferred into a 
screw-capped vial and stored at -70°C.
Dilutions were prepared from the stock of cloned virus 
suspension and cell monolayers were infected as above. A single 
plaque was picked to produce a second cloned virus suspension and 
by repeating the process three times the cloned virus preparation 
was derived. The virus was retested at 31 ®C and 37®C before and 
after virus stocks were made by plaque assay. This virus was 
designated FCV-ts.
Stock FCV-ts virus
Ten 9 cm plates each containing approximately 5 x 10^ FEA 
cells were infected with 1 ml containing 3.8 x 10^ pfu/ml of 
FCV-ts. Adsorption for 2 hours at 31®C was followed by adding 3 ml 
DFC-10 to each plate. These plates were incubated at 31 ®C for 3 
days. The infected cell suspension was centrifuged at 2,000 rpm for
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10 minutes to remove cell debris and the fluid was filtered through 
a 0.22 ym filter. The supernatant fluid was dispensed in 0.5 ml 
volumes and stored at -70°C.
Results
Toxicity of 5-FU
The cell monolayers which were incubated at 37*C for 24 hours 
with different concentrations of 5-FU showed complete cellular 
destruction with the higher concentration of 500 yg/ml 5-FU and
less with 200 yg/ml. The cell monolayers grew normally with the
other concentrations of 5-FU (Table 2.1).
Growth of FCV-K in presence of 5-FU
A  CPE was observed in the plates containing different 
dilutions of 5-FU after 3 days' incubation at 3l°C. The extent of 
the CPE was obviously higher with lower concentrations of 5-FU. 
This was confirmed when plaque assays were carried out on the
harvested fluids as shown in Table 2.2.
Isolation of FCV-ts mutant virus
Twelve clones showed CPE at 31®C but none or apparently less 
at 37®C. These clones were selected and assayed at the two
temperatures. Only one showed a difference in titre (3.0 x 10^ 
pfu/ml at 31®C and 1.7 x 10^ pfu/ml at 37®C) as shown in Table
2.3. The other eleven clones showed the same titre at 31®C or 37®C
(approximately 1 x 10^).
Plaque purification of mutant virus
The titre of the FCV-ts mutant stock prepared as described in 
the Materials and Methods was 3.8 x 10^ at 31 "C and 5.0 x 10^ at 
37*C after three rounds of plaque purification, as shown in Table
2.4.
TABLE 2.1
Toxicity of 5-FU for FEA cells
Concentration of 
5-FU (yg/ml)
Cell lysis
500 Complete
250 +
200 +
125 ±
100 -
62 -
50 -
30
+ = some cell lysis^ 
- = no cell lysis.
TABLE 2.2 3[
Plaque assay of FCV-K treated with 5-FU
Concentration of 
5-FU (yg/ml)
Virus titre 
(pfu/ml)
.
5 0 0 2 . 5  X  1 0 4
2 5 0 1 . 7  X 1 0 4
200 1 . 6  X  1 0 4
1 2 5 1 . 5  X 1 0 5
100 ^ ■ 1 . 4  X  1 0 5
6 2 2.0 X 10^
5 0 2 . 2  X  1 0 5
3 0  . 3 . 0  X 1 0 ^
TABLE 2.3 31
Plaque assay of cloned FCV-ts
Virus dilution 
(logio)
31°C
Plaques/Well
37°C 
Plaques/Well
- 2 Confluent 8, 9
- 3 Confluent 3, 4
- 4 Confluent 0, 0
- 5 14, 16 0, 0
— 6 8, 10 0, 0
- 7 6, 15 0, 0
Titre (pfu/ml) 3.0 X 10* 1.7 X 103
3 2
TABLE 2.4
Plaque assay ôf plaque purified FCV-ts
Virus dilution 
(logio)
31 ®C
plaques/plate
37°C
Plaques/plate
- 3 Confluent 2, 3
- 4 Confluent 0, 0
- 5 19, 19 0, 0 1
— 6 0, 0 0, 0
- 7 0, 0 0, 0
Titre (pfu/ml) 3.8 X 10* 5.0 X 10^
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Discussion
The mutagen 5-FU was titrated on FEA cells and the highest 
concentration which was found to be relatively non— toxic was 200 
yg/ml* Higher concentrations showed toxic effects and cell lysis. 
This mutagen was also found to inhibit the growth of the virus, 
FCV—K, in FEA cell monolayers and the degree of inhibition was 
found to increase with increasing doses of mutagen.
Virus grown from cultures exposed to 200 yg/ml of 5-FU was 
cloned and 12 clones which appeared to grow at 31 ®C and not at 37®C 
were selected. These clones which were isolated from mutagenized 
stock were propagated in cells until screening for temperature 
sensitivity had been completed. Only one of these clones was found 
to be temperature sensitive when the viruses were titrated at each 
temperature. This might be attributed either to the existence of 
revertant viruses or to the quantitative differences in the viral 
doses which were plated in the original screening process. The 
difference in the titre at 31 ®C or 37®C was approximately 
760-fold. Since only one mutant was isolated it is not known 
whether this was a pre-existing mutant in the FCV-K virus stock or 
whether the 5-FU increased the rate of generation of mutants.
The small number of stable ^  mutants of FCV which kept their 
ts characteristic was also shown for other viruses. Eastman and 
Blair (1985) in a study of a togavirus, Japanese encephalitis 
virus, using 5-FU in concentrations between 100 and 200 yg/ml, 
managed to recover only 18% of the potentially temperature 
sensitive clones after purification. They attributed this small 
proportion to the high rate of reversion to wild type with this 
virus. However the mutants which were selected grew at least 
ICO-fold better at 33°C than at 41®C.
The concentration of 5-FU has been suggested in some studies 
to be connected to the number of mutants, while in other studies it 
w^as found to be unrelated. Gadkari and Pringle (1980) in a study 
on Chandipura virus found no association between the concentration
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of 5-FU and the number of ^  mutants when using BHK-21 cells but on 
using BSC-1 cells there was a significant increase in the frequency 
of isolation of ts mutants with increasing concentration of 5—FU up 
to 200 yg/ml. In another study on vesicular stomatitis virus 
Pringle et a l . (1971) found a comparable increase in mutant number 
with increase in 5-FU concentration.
The stock of FCV-ts which was made was used subsequently in 
the studies to characterise the mutant described in Chapters 3, 4 
and 5 and in the experiment in which kittens were exposed to the 
virus which is described in Chapter 6.
CHAPTER 3
GROWTH CURVE OF THE FCV ts MUTANT
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Introduction
In order to carry out experiments to characterise the FCV ts^  
mutant it was first necessary to establish the growth curve of the 
virus, as far as possible under one-step growth conditions. In 
this chapter a growth curve experiment is described in which feline 
embryo cells were infected with the virus at a multiplicity of 
infection of 1. The amounts of extracellular and cell-free virus 
were determined at intervals after infection by plaque assay and 
the proportion of infected cells was found by immunofluorescence.
Materials and Methods
FCV-ts growth curves
FEA cell monolayers in 12-well cluster plates were obtained by 
incubation of 1 x 10^ FEA cells in each well for 24 hours at 37*C. 
The cells were infected with 1 x 10^ pfu of FCV-ts in 0.5 ml. 
After an adsorption time of 60 minutes at 3l*C the inocula were 
removed and the cultures were washed twice with DFC-1. Three ml of 
DFC— 1 were added to each well before re-incubation at 31*C. 
Immediately, and at 2, 4, 6, 10, 12, 14, 18, 20, 22 and 24 hours 
afterwards the medium was removed from 2 wells, transferred to a 
small screw-cap vial and stored at -70*C. These samples 
represented the extracellular virus. Two ml of fresh DFC-1 was 
then added to each well and by scraping the monolayers off into 
medium a cell suspension was produced. The suspension was frozen 
and thawed in a dry ice/ethanol bath, then centrifuged for 10 
minutes at 2,000 rpm. The supernatant fluid was stored at -70°C. 
These samples represented the cell-associated virus.
The extracellular and cell-associated virus were then titrated 
by plaque assay.
Immunofluorescence
An indirect immunofluorescence method was used at the same 
time as the growth curve experiment to determine the proportion of 
infected cells. Monolayers were produced on 8-well microscope 
slides (Flow Laboratories). Each 7 mm well was seeded with 2.5 x 
10^ FEA cells in 25 ml DFC-lO and virus suspension diluted to 
contain 2.5 x 10^ pfu in 25 ml DFC-1 was added (i.e. a virus-cell 
ratio of 1). After 10 hours' incubation at 3l°C, the slides were 
washed twice for 2 minutes with PBS and the cells were fixed in 
methanol for 3 minutes at room temperature and dried in air. A 
volume of 25 pi of anti-FCV cat serum diluted 1:10 in PBS was added 
to each well. This serum was from a cat which had been infected 14 
days previously with the G-1 strain of FCV by Ormerod e t _ ^ .
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(1978). The slides were incubated at 37°C for 1 hour in a 
humidified box. The serum was then removed from each well and the 
slides were washed twice in PBS for 3 minutes, dipped in water and 
dried at 37®C.
A  volume of 25 yl of FITC-conjugated anti-cat globulin (Miles 
Laboratories) diluted 1:30 in PBS was then added to each well. The 
slides were re-incubated at 37*C for 1 hour in a humidified box. 
The antibody was removed and the slides were washed twice in PBS 
and once in water and then dried. Each well was examined for the 
presence of immunofluorescence in a Leitz Orthoplan microscope 
using an ultraviolet light source. A 25X water immersion 
objective was used.
The proportion of cells containing FCV antigen was determined 
by counting at least 400 cells.
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Results
Growth curve of FCV-ts on FEA cells
Hils experiment was designed to examine the rate of synthesis 
of the mutant virus, the efficiency of virus release from 
infected cells and the total virus yields.
The growth of FCV t£ is shown in Tables 3.1 and 3.2 and in 
Fig. 3.1. The extracellular virus growth curve showed that the end 
of the eclipse phase occurred at around 10 hours after infection 
(Table 3.1). The extracellular virus titre increased rapidly 
between 8 and 12 hours but continued to rise up to 20 hours.
The cell-associated virus growth curve is shown in Table 3.2. 
The initial rise in the cell-associated virus occurred 8 hours 
after infection and continued until 24 hours after infection. At 
this time the CPE was extensive, involving almost all the cells.
Immunofluorescence
FEA cells were infected with FCV mutant and stained 10
hours after infection with anti-FCV cat serum followed by 
FITC-conjugated anti-cat globulin. Fluorescence was limited to
cell cytoplasm and specific fluorescence was observed in approx­
imately 37% of the cells as shown in Table 3.3.
TABLE 3.1
Growth curve of FCV ts: extracellular virus
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Time in 
hours
Dilution of 
virus (logio)
Number of 
plaques/plate
Titre
(pfu/ml)
0 0, 0 IQl
2 0, 0 lOl
4 0, 0 loi
6 0, 0 101
8 0, 0 loi
10 -4 4. 6 1.0 X 104
12 —4 6, 11 1.6 X 105
14 -5 3, 4 7.0 X 1q 5
18 .-5 2. 7 9.0 X 1q 5
20 -5 12, 13 9.0 X 10&
22 —6 5, 2 7.0 X 10^
24 —6 4, 3 7.0 X 106
TABLE 3.2
Growth curve of FCV ts: cell—associated virus
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Time in 
hours
Dilution of 
virus (logio)
Number of 
plaques/plate
Titre
(pfu/ml)
0 -2 3. 5 8.0 X 1q 2
2 -2 4, 4 8.0 X 102
4 -2 2, 6 8.0 X 102
6 -2 10, 10 2.0 X 103
8 -3 19, 22 4.1 X 104
10 -3 16, 29 4.0 X 104
12 -4 9, 9 1.8 X 105
14 -4 6, 5 1.1 X 105
16 -4 5, 5 1.0 X 1q 5
18 —4 7, 13 2.0 X inS
20 -4 8, 7 1.5 X 1Q5
22 -4 13, 10 2.3 X  105
24 -4 25, 35 6.0 X 10^
TABLE 3.3
Proportion of FCV ts infected cells
41
Microscope
field
Number of cells with 
FCV antigen
Total number 
of cells
1 31 86
2 51 116
3 24 86
4 49 126
Total 155 424
% with antigen 37%
4 2
Fig 3.1 Growth curve of FCV-ts
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Discussion
The majority of conditional lethal mutants of animal viruses 
which have been described are ts mutants. These mutants are unable 
to multiply in susceptible cells at high temperatures but are 
unrestricted at lower temperatures. The plaque morphology and 
growth characters can often be used to distinguish mutant and wild 
type virus (Pringle, 1984). In this study the growth curve of the 
FCV-ts mutant was studied at the permissive temperature of 31 ®C. 
Cell associated and extracellular virus were measured.
As indicated by the extracellular virus growth the end of the 
eclipse occurred at around 8 hours after infection. In a study of 
the growth of the wild type strains Gj, G2 and G^g at 3 7 °C Ormerod 
(1978) found that the latent and eclipse periods ended at 
approximately 2 hours after infection with a rapid rise in 
intracellular virus between 2 and 3 hours. This experiment served 
to demonstrate the characteristic, rapid single step growth curve 
of FCV which was very similar to that of picornaviruses (Howes and 
Melnick, 1957).
The growth curve of FCV-ts at 31 ®C was prolonged compared to 
that of wild type strains at 37*C, taking 18-24 hours to reach 
maximum yields. However the curve had the general appearance of a 
one-step growth curve.
One problem about carrying out this experiment was that the 
titre of the stock FCV-ts was quite low (3.8 x 10^ pfu/ml) compared 
to that of wild type FCV grown at 37*C which is often in excess of 
1q 8 pfu/ml. Therefore the multiplicity of infection in the 
experiment was only 1 compared to up to 100 in the experiments of 
Ormerod (1978). However even at this relatively low multiplicity 
of infection the proportion of cells which was estimated to be 
infected on the basis of containing FCV antigen by 
immunofluorescence was 37%. This figure was comparable to the 28% 
achieved with wild type virus by Ormerod (1978).
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These experiments described the general characteristics of the 
growth of FCV-ts in FEA cells and the results permitted the design 
of experiments to find the stage of viral growth which was 
temperature sensitive, as described in Chapters 4 and 5.
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INITIAL CHARACTERISATION OF THE FCV ts MUTANT
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Introduction
From the result of the experiments described in Chapter 2 it 
was clear that the growth of FCV-ts was severely inhibited at the 
non-permissive temperature of 37*C compared to the permissive 
temperature of 31®C. In this chapter, experiments are described 
which aimed to find the stage of the growth cycle of the virus at 
which the temperature-sensitive event occurred.
Three experiments were done. In the first, the virus was 
incubated at each temperature for 6 hours to find whether or not 
the virus particles themselves were thermolabile. In the second, 
the virus was inoculated on to feline embryo cells to examine the 
effect of temperature on the earliest stage of the growth cycle, 
virus adsorption. In the third experiment, cells were infected 
with the mutant, incubated at 3l°C and then at intervals after 
infection were shifted to 37*C and incubated until 24 hours after 
infection. It was expected that this experiment would show whether 
an early or late event in the growth cycle was temperature 
sensitive.
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Materials and Methods
1• Effect of temperature on the FCV-ts particle.
A  stock of FCV-ts was diluted to 1 x 10^ pfu/ml, using DFC-1 
as a diluent and was dispensed in 2 ml volumes in 5 ml plastic 
Lotties (Sterilin). The samples were placed in a waterbath at 37®C 
or 3l*C. Immediately afterwards and then after 6 hours, 1 ml 
volumes of virus were removed and stored at — 70*C. The infectivity 
of the samples was subsequently determined by plaque assay.
2. Effect of temperature on adsorption of FCV-ts
Two series of FEA cells in 12-well plates were infected with 
0.5 ml per well of a ten-fold dilution of FCV-ts (3.8 x 10^ 
pfu/ml). These cells were incubated for 2 hours at 31®C or 37®C, 
the inoculum was removed and the cells were washed twice in DFC-1. 
Two ml of overlay medium were applied and the infected cells were 
re-incubated at 3l°C for 2 days. The cells were then fixed and
stained and the plaques were counted.
3. Temperature shift experiment
Flve-cm plates were seeded with 2 x 10^ FEA cells in 4 ml 
DFC-10 and were incubated for 24 hours at 37°C. The cells were 
then infected with 3.8 x 10^ pfu in 1.0 ml. After an adsorption 
time of 2 hours at 31 ®C the inocula were removed and the cultures 
were washed twice in DFC-1. Four ml of DFC-1 were added to each 
plate before re-incubation at 3l°C. Immediately and at 2, 4 or 6 
hours afterwards plates were transferred to 37°C. At 24 hours
after infection the cultures were harvested. The infected cells
were scraped off into the medium and were centrifuged at 2,000 rpm 
for 10 minutes. The supernatant fluids were dispensed in 0.5 jil 
volumes and stored at -70*C then later assayed to obtain the tit.e 
of extracellular virus.
Results
^• Effect of temperature on the FCV-ts particle
Table 4.1 shows the effect of incubating the FCV-ts particle 
at 3l*C or 37®C for 6 hours. During this incubation period there 
was a fall in the titre of virus by a factor of about 10 but there 
was little difference in titre between incubation at 3l°C (2.2 x 
10^ pfu/ml) or 37°C (4.3 x 10^ pfu/ml).
2. Effect of temperature on the adsorption of FCV-ts
As shown in Table 4.2, after adsorption for 2 hours at 3l°C or
37®C followed by incubation for 2 days under an overlay agarose at
3l°C, there was very little difference in titre between virus 
adsorbed at 3l°C (1.8 x 10^ pfu/ml) or 37°C (2.9 x 10^ pfu/ml).
3. Temperature shift experiment
In this experiment the infected cells were incubated at 31 ®C 
for 2, 4, 6 or 24 hours after inoculation. At each time a plate 
was removed and the culture was harvested to determine the titre of 
extracellular virus as described in Chapter 3. At the same time 
another plate was shifted to 37®C and was incubated at that 
temperature until 24 hours after infection when it was harvested.
As shown in Table 4.3 the titre of virus produced after 24 
hours of continuous incubation at 31 ®C was 1.4 x 10^ pfu/ml. 
However, when the virus infected cultures were shifted to 37®C the 
amount of virus produced after 24 hours was only moderately greater
than at the time when the cultures were shifted, at 2, 4 or 6 hours
following infection.
TABLE 4.1
Effect of temperature on the FCV-ts virus particle
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Time of Dilution No . of plaques Titre of virus
incubation of virus per well (pfu/ml)
(hours) (logio) 31 ®C 37°C 31°C 37°C
0 -4 10, 19 16, 18 2.9 X 105 3.4 X 10^
6 -3 9, 13 21, 22 2.2 X lo4 4.3 X 10^
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TABLE 4.2
Effect of temperature on adsorption of FCV-ts
Dilution No. of plaques Titre of virus
of virus per vWeVV (pfu/ml)
(logic) 31*C 37®C 31*C 37*C
-5 7, 11 14, 15 1.8 X 106 2.9 X 10^
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TABLE 4.3
Temperature shift experiment
31 ®C 31*C - 37 *C
Time after Dilution Dilution
infection of virus No. of Titre of virus N o . of Titre
(hours) (logio) plaques (pfu/ml) (loglO) plaques (pfu/ml)
2 -2 32 3.2 X 103 -3 12 1 .2 X 104
4 -3 18 1.8 X 104 -3 45 4 .5 X 104
6 -3 10 1.0 X 104 -3 59 5 .9 X 104
24 -5 14 1.4 X 10^
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Discussion
Three experiments were done in this chapter to begin to 
characterise the FCV-ts mutant. The first experiment showed that 
the FCV-ts virus particle was not itself temperature sensitive 
because it was quite stable when incubated at the non-permissive 
temperature over a period of 6 hours.
Ormerod (1978) used the same method to measure the stability 
of his wild type FCV strains at 37®C and found that the three 
isolates (G^, G£, G^g) were apparently of equal stability at this 
temperature with a half life of approximately 5 hours. A similar 
finding was reported for vesicular exanthema virus variants 
(McChain and Hackett, 1958).
In principle, conditional lethal mutation can be obtained in 
any gene whose function is essential for normal replication. This 
is because a change in an amino acid may produce a conformational 
change which affects the stability of the whole molecule at high 
temperature (Pringle, 1984). Baltimore (1968) in a study of 
poliovirus mutants described the characterisation of the phenotypic 
properties of the virus and found that the virions from three of 
these mutants were much more heat sensitive at the non-permissive 
temperature of 45°C than wild type virions. On the other hand, 
virions from another mutant were as heat resistant as wild type 
virions. It was also found that one of these mutants was probably 
a capsid mutant.
The second experiment indicated that the first stages of 
infection of cells by the FCV-ts virus were also not temperature 
sensitive. The adsorption of virus to FEA cells over a period of 2 
hours was equally efficient at 3l*C and 37*C. From these results 
it appeared that the temperature sensitive event occurred early in 
the growth cycle of the virus but after virus adsorption to the 
cells.
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Generally mutation is found to block a specific viral
function. The time in the virus life cycle at which that function 
is required can often be determined by temperature shift
experiments (Ramig, 1985).- The third experiment in this study 
suggested that the temperature sensitive stage in viral growth 
began soon after virus adsorption. Shifting the temperature from 
31®C to 37®C even 2 hours after infection resulted in only a 3-fold
increase in virus yield after 24 hours compared to a 500-fold
increase in yield after 24 hours' growth at 31®C. Similar results 
were obtained when the temperature was shifted 4 and 6 hours after 
infection.
The lesion might be in a viral polymerase molecule or in 
the capsid protein. However the results obtained in this chapter 
could not distinguish between these alternatives. The experiments 
described in the next chapter were designed to determine whether 
the t^ lesion affected RNA synthesis and therefore might be in a 
polymerase gene.
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Introduction
The site of the temperature sensitive lesion in FCV-ts might 
be in the gene coding for .the capsid protein or a non-structural 
protein such as an RNA polymerase. In this chapter attempts were 
made to distinguish between these possibilities. The capsid 
protein of FCV is well-defined although there is controversy about 
whether or not a larger precursor molecule is synthesised in 
infected cells (Black and Brown, 1975, 1977; Komolafe, 1978). If 
the ts lesion were in the capsid protein it might be expected that 
the virion itself would be thermolabile by comparison with studies 
on other small RNA-containing viruses (Polatnick and Richmond, 
1980). However, the results in the previous chapter indicated that 
the infectivity of the virion was not affected by incubation at the 
non-permissive temperature.
In this chapter virus-specific RNA synthesis was studied in 
FCV ts-infected cultures. Very little is known about the 
calicivirus-induced RNA polymerase. Such an enzyme must be 
synthesised in calicivirus-infected cells in order that viral RNA 
is replicated. If the lesion were in this molecule it might be 
expected that RNA synthesis in infected cells would be reduced at 
the non-permissive temperature. Accordingly RNA synthesis in 
FCV-ts infected cells was studied by investigating the 
incorporation of %-uridine into acid-precipitable radioactivity in 
infected cells at the permissive and non-permissive temperature. 
This incorporation was compared with that observed in FCV strains 
which grew at 37°C. These were the vaccine FCV-K from which the ^  
mutant was derived and FCV-ts R which was a revertant of FCV-ts, 
the isolation of which is described in Chapter 6.
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Materials and Methods
Cell culture
Plastic 3 cm plates were seeded with 6 x 10^ FEA cells in 2 ml 
DFC-10 medium and incubated at 37°C for 24 hours.
Viruses
FCV-ts at 1 X 10^ pfu/ml was used for the following 
experiments.
FCV-K was derived from Katavac-CH vaccine as described in 
Chapter 1.
FCV-tsR was isolated from a cat inoculated with FCV-ts as 
described in Chapter 6.
Experiment 1 : Effect of actinomycin-D on RNA synthesis in FEA
cells
Two sets of samples were prepared according to the 
actinomycin-D concentration. In the first, concentrations were 0, 
2, 10 and 50 pg/ml and in the second, 0, 0.6, 2.5 and 10 yg/ml.
After removing the media from the plates of confluent FEA 
cells, 2 ml of different actinomycin-D concentrations was added to 
the cells in each plate, which were then incubated at 31°C. After 
one hour this medium was replaced by 2 ml of fresh actinomycin-D at 
the same concentration together with 5 yCi/ml ^H-uridine of 
specific activity 40 Ci/mmol (Amersham International). These 
plates were incubated at the same temperature for another hour. 
After incubation the cells were scraped off, the remaining cells 
were washed off with 2 ml PBS and the whole culture was transferred 
into a 10 ml plastic conical tube. The suspensions were 
centrifuged at 2000 rpm for 5 minutes. The supernatant fluids were 
discarded carefully and the sediments were resuspended in 10 ml of
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5Z cold trichloracetic acid (TCA). After vigorous mixing, the 
suspensions were incubated at 4®C for 10 minutes, after which time 
they were collected on 2.5 cm Whatman GF/C filters using a 
Mlllipore filter manifold. The filters were washed twice with 5 ml 
cold 5% TCA and then with 5 ml of ethanol. After drying at 60°C 
for 30 minutes the filters were transferred to plastic vials to 
which was added 10 ml of Aqualuma (LKB) scintillation fluid. The 
radioactivity in the samples was counted in a Packard scintillation 
spectrometer. Each sample was counted so that the standard error 
was less than 5%.
Experiment 2 : Effect of FCV-ts infection on RNA synthesis in
FEA cells
I
Uninfected and cells infected with FCV-ts were used and RNA 
synthesis was measured. After 16 hours of incubation at 31 ®C at 
which time there was developing CPE but while the cells were still 
attached to the plates, 200 yl of a mixture of actinomycin-D (2.5 
pg/ml) and %-uridine (5yci/ml) was added. After another period of 
incubation for 2 hours the cells were scraped off and processed as 
in the previous experiment.
Experiment 3 : Effect of temperature shift on virus-specific
RNA synthesis in FCV-ts infected FEA cells
Uninfected and infected FEA cells were incubated for 24 hours 
at 31 ®C. The 200 pi actinomycin-D (2.5 yg/ml) and % - u r idine was 
added. Half of the plates of cells were re-incubated at 3l*C and 
half were shifted to 37®C for 3 hours. The TCA-precipitable cpm 
was then established as before.
Experiment 4 : Effect of temperature shift on virus-specific
RNA synthesis in FCV-K or FCV-tsR infected FEA cells
The effect of temperature shift on two FCV strains which grew 
at 37*C was studied. The two viruses were FCV-K, the vaccine virus 
from which the FCV-ts mutant was derived, and FCV-tsR the revertant
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virus isolated from FCV-ts, described in Chapter 6, which grew at 
the non-permissive temperature. The experiment was carried out as
for Experiment 3. The cells were infected at a multiplicity of
infection of 2 pfu/cell and the temperature was shifted after
incubation at 31°C for 24 hours.
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Results
Experiment 1 :_____Effect of actinomycin-D on cellular RNA
synthesis
Control samples which had not been incubated with
actinomycin-D showed the highest incorporation of into
acid-precipitable material which reflects the amount of RNA 
synthesis in the cells during the period of exposure to 
^H-uridine. Increasing the actinomycin-D concentration decreased 
the incorporation of radiolabel.
From these results it was decided to use 2.5 yg/ml in the 
experiment to investigate the incorporation of ^H-uridine into 
FCV-infected cells. (Table 5.1).
Experiment 2 : Effect of FCV-ts infection on RNA synthesis in
FEA cells
The aim of this experiment was to find if virus-specific RNA 
synthesis could be detected in FEA cells treated with
actinomycin-D, following infection with FCV-ts.
The result of this experiment, shown in Table 5.2, was that 
there was no increase in RNA synthesis in the infected cells. 
Therefore, the next experiment was to investigate RNA synthesis 
later after infection, at 24 hours when the CPE was more advanced. 
Also in this experiment the effect on RNA synthesis of shifting the 
temperature from 31“C to 37“C was studied.
Experiment 3 : Effect of temperature shift on virus-specific
RNA synthesis in FCV-ts infected FEA cells
The purpose of this experiment was to find if virus-specif_c 
RNA synthesis in FCV-ts infected cells was affected by shifting the 
temperature of incubation from 3l°C to 37®C. The results are in 
Table 5.3.
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Table 5.1
Effect of actlnomycln-P on cellular RNA synthesis
Experi­
ment
Actinomycin-D
concentration
(yg/ml)
%  incorporation 
(cpm per sample)
Mean cpm
A 0 17694, 17791, 12334 15939
2 1685, 1899, 2812 2132
10 797, 3591, 639 598
50 466, 4681, 441 458
B 0 6819, 7135 8977
0.6 1232, 1352 1292
2.5 425, 524 474
10 660, 440 550
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Table 5.2
Effect of FCV-ts infection on RNA synthesis in FEA cells
Treatment of 
cells
uridine incorporation (cpm) 
uninfected infected
cpm/plate mean cpm/plate mean
Actinomycin-D 
(2.5 yg/ml)
725, 526 550 516, 572 600
No actinomycin 4281, 3555 3500 3095, 3909 3600
Table 5.3
Effect of temperature shift on RNA synthesis 
in FCV-ts infected cells.
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Temperature 3h --uridine incorporation (cpm)
shift uninfected infected
cpm/plate mean cpm/plate mean Ratio*
31°C - 31°C 2600, 2432 2516 9655, 9707 9681 3.8
31°C - 37°C 1459, 1352 1405 2032, 2026 2029 1.4
* Ratio of infected cell cpm : uninfected cell cpm.
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The conclusions of this experiment were first, that at 24 
hours after infection, virus-specific RNA synthesis can be detected 
because there is 4-fold increase in incorporation of ^H-uridine 
into TCA-precipitable cpm in the infected cells compared to 
uninfected cells. Secondly, by shifting the temperature from the 
permissive temperature (31°C) to the non-permissive temperature 
(37®C), the incorporation of ^H-uridine into TCA-precipitable cpm 
was decreased by a factor of 5. This indicated that RNA synthesis 
was affected by the increase in temperature and suggested that the 
temperature-sensitive lesion involved decreased RNA synthesis 
perhaps as a result of a thermolabile RNA polymerase.
Experiment 4 : Effect of temperature shift on virus-specific
RNA synthesis in FCV-K or FCV-tsR infected cells
This experiment was designed to examine viral RNA synthesis in 
FEA cells infected with viruses which grew as well at 37®C as at 
31*C under conditions of temperature shift. The results are shown 
in Table 5.4.
For FCV-K there was a slight reduction in the amount of 3p[ 
which was incorporated into acid-precipitable material when the 
temperature was shifted suggesting that this virus may be slightly 
ts. For the revertant virus, FCV-tsR, there was a very slight 
increase in the which was incorporated suggesting that it could 
direct the synthesis of viral RNA at 37®C as well as at 31®C.
Table 5.4
Effect of temperature shift on virus-specific
RNA synthesis in FCV-K or FCV-tsR infected cells
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Virus Temperature shift 3-H uridine 
cpm/plate
incorporation
mean
FCV-K 31°C 31 °C 1599, 1871 1735
31°C 37°C 946, 963 958
FCV-tsR 31 °C 31 °C 1319, 1500 1409
31 °C 37°C 1735, 1788 1761
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Discussion
The experiments described in this chapter were designed to
find if virus-specific RNA synthesis was affected when the ts FCV 
mutant was grown at the non-permissive temperature. If so, it
would suggest that the t^ lesion was in the gene which codes for an
RNA polymerase, as yet unidentified.
The first experiment confirmed that, as expected, 
actinomycin-D inhibited RNA synthesis in FEA cells and the 
concentration required to reduce synthesis to less than 5% of the 
level in uninfected cells was established. RNA synthesis was 
measured by the incorporation of into acid-precipitable
radioactivity. This concentration (2,5 yg/ml) of actinomycin-D was 
then used in subsequent experiments.
In the second and third experiments it was found that 
infection of FEA cells with FCV-ts dramatically increased RNA 
synthesis after 24 hours’ incubation at 31®C by a factor of 4 in 
the presence of actinomycin-D. It is assumed that this increase 
was due to virus-specific RNA synthesis although the RNA was not 
characterised further.
Also in the third experiment the effect on virus-specific RNA 
synthesis of shifting the temperature of incubation from 31®C to 
37®C was investigated. It was found that this temperature shift 
reduced RNA synthesis in FCV-ts infected cells by a factor of 5. 
These results indicated that the lesion was in a site which 
affected RNA synthesis.
The most likely reason for this result is that the lesion 
is in a n  RNA polymerase gene and that the RNA polymerase does not 
function properly at the non-permissive temperature. Many examples 
of such mutants are known in other RNA-containing viruses: for
example, togaviruses (Eastman and Blair, 1985), foot-and-mouth 
disease virus (Richmond and Polantnick, 1976) and the rhabdovirus, 
vesicular stomatitis virus (Wunner and Pringle, 1972).
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On the other hand McCahon (1981) reported that in foot-and- 
mouth disease virus approximately 83% of the mutations were in the 
capsid protein region and a similar distribution was found with
poliovirus (Cooper, 1968, 1971).
Another possibility is that viral RNA is synthesised normally 
but is not shielded from degradation after shift-up to the 
non-permissive temperature as suggested for mutants of foot-and-
mouth disease virus by Polantnick and Richmond (1980), perhaps 
because association with capsid protein is affected. In this case 
the lesion might be in the capsid protein gene although
phenotypically it is the integrity of the viral RNA which is
affected by the higher temperature.
CHAPTER 6
INFECTION OF CATS WITH THE FCV-ts MUTANT
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Introduction
At the beginning of this study it was believed that a 
mutant of FCV might be useful as a vaccine. Temperature sensitive 
mutants of FHV are used in cats as intranasal vaccines and have 
been very successful (Slater and York, 1976). These viruses grow 
locally in the upper respiratory tract and induce a good immune 
response. Also their growth is limited to a few days (Orr et a l ., 
1980) which reduces the chance of virus spreading to in-contact 
cats. In contrast, the non-temperature sensitive FCV component in 
the same vaccine grows for a period of several weeks in the 
oropharynx (0. Jarrett, personal communication). It was hoped that 
the FCV-ts virus might behave in a similar way to the vaccine FHV.
In this chapter an experiment is described in which FCV-ts was 
administered to kittens by the intranasal route and the kittens 
were examined subsequently for virus excretion. Unexpectedly virus 
was found to »be present in the oropharynx for up to 26 days 
following infection. Virus isolated from a kitten at the end of 
this period was checked for temperature sensitivity and was found 
to have reverted, growing as well or better at 37®C than 31®C. A 
similar revertant was then found when FCV-ts was passaged in cell 
culture.
66
Materials and Methods
Animals
Four kittens, 13 weeks old, were obtained from the breeding 
colony of the University of Glasgow, Department of Veterinary 
Pathology. These kittens were separated from the queens when they 
were 12 weeks old and transferred to experimental accommodation. 
They were housed together in a room with a floor area of 12 m ^ ,
Infection of cats
FCV-ts was diluted in DFC-1 medium to a concentration of 1.0 x 
10^ pfu/ml and a volume of 1 ml was given intranasally to each 
kitten using a syringe without a needle. A volime of 0.5 ml of 
virus inoculum was instilled into each nostril.
Sampling of cats
Oropharyngeal swabs were taken on the day before Infection, on 
the day of infection (day 0), and then on each day for the first 2 
weeks of the experiment, after which samples were taken twice 
weekly until the end of the experiment.
Rectal temperatures were taken before infection as above and 
for the first 12 days following infection.
Processing of samples
The oropharyngeal swabs were taken with the aid of sterile 
cottonwool swabs on wooden sticks (Exogen), The swab was broken 
off into a plastic bottle containing 2.5 ml of transport medium 
(Leibovitz L-15 medium with 20% FBS, 500 yg/ml U n c o m y c i n  sulphate 
and 2.5 pg/ml amphotericin B) which was then sealed. In the 
laboratory the fluid was transferred from the bottles to conical 
ce^itrlfuge tubes and centrifuged at 2,000 rpm for 10 minutes. The 
upper 2 ml of the supernatant fluid was removed and a volume of
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1 ml was transferred to each of 2 vials which were stored at — 70®C 
prior to virus isolation.
Isolation of virus
Samples from each cat were diluted to 2 ml and were inoculated 
Into each of two confluent FEA cell cultures in 5 cm plates and 
adsorption was allowed for 2 hours at 31®C followed by replacement 
of the medium with 4 ml DFC-1. The plates were incubated at 31 ®C 
and were examined daily until a CPE was observed, or 4 days had 
elapsed. At the end of 4 days plates not showing CPE were regarded 
as negative.
Revertant virus isolated from cats '
An isolate made from cat 2 at 26 days after infection was 
passaged once by inoculating 1.0 ml of the culture fluid into a 
confluent FEA cell culture in a 5 cm plate and incubating at 31 ®C 
for 2 days. The infected cells were harvested, centrifuged at 2000 
rpm for 10 minutes and the supernatant fluid was filtered (0.22 ym) 
and stored at -70°C until use. This sample was then cloned once as 
described in Chapter 3 and subsequently titrated at 31°C or 37®C by 
plaque assay. For comparison the virus used to inoculate the cat 
was titrated simultaneously at each temperature.
Revertant virus isolated from cell culture
Confluent FEA cells in a 5 cm plate were infected by 2.0 ml of 
FCV-ts containing 3.8 x 10^ pfu/ml and left 2 hours for adsorption 
after which the plate was incubated in 3l°C for 2 days. The cells 
were harvested and above procedure was repeated twice. Then the 
infected cell suspension was centrifuged at 2000 rpm for 10 minutes 
to remove cell debris and the fluid was filtered through a 0.22 ym 
filter. The supernatant fluid was dispensed in 0.5 ml volumes and 
stored at -70*C. The virus was assayed at 31®C or 37®C.
Results
Clinical examination
No clinical signs or elevation of rectal temperature was noted 
following infection as shown in Table 6.1.
Virus recovery from the oropharynx
Oropharyngeal swabs taken from the 4 cats one day before 
inoculation, on the day of inoculation and after one day following 
inoculation were negative for FCV. Table 6.2 shows the results of 
the isolation of the virus from the oropharynx of infected cats for 
a period of 43 days. After 24 hours all the cats began to excrete 
the virus except Cat 1 which excreted virus after 48 hours. All 
the cats continued to excrete virus for 26 days. Subsequent 
oropharyngeal swabs taken from the cats proved negative.
Revertant virus isolated from cats
The results of this experiment showed that virus could be
isolated from the oropharynx of cats inoculated with FCV-ts over a 
priod of 26 days. It had been expected that the period of virus 
excretion would be much shorter and more like the excretion of the
temperature sensitive FHV in the Katavac-CH vaccine as shown in
Table 6-3. In fact, the duration of FCV excretion was quite 
similar to that of the wild type FCV Katavac-CH vaccine virus (up 
to 40 days) as shown in Table 6.3. Data for Table 6.3 were
obtained form 0. Jarrett and are based on a previous experiment 
carried out as above.
One reason for this prolonged excretion might be that a 
revertant had arisen during growth of the virus in the cats wbich 
could grow at 37®C and might be more invasive in the oropharynx. 
Accordingly, samples taken from Cat 2 were inoculated on to FEA 
cells which were incubated at 31 ®C or 37®C. The virus used as the 
inoculum for the cats was also titrated at the two temperatures.
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TABLE 6.1
Rectal temperatures of inoculated cats
Cat Rectal temperature! (*C)
No • Days after infection
-1 0 I 2 3 4 5 6 7 9 12
1 38.0 38.6 39.3 38.2 38.4 38.7 38.8 38.4 39.3 38.6 38.0
2 38.8 38.5 39.1 38.2 38.6 39.1 38.4 38.4 39.0 39.0 38.2
3 38.8 38.6 38.2 38.3 39.1 39.3 39.5 40.2 39.7 38.8 38.3
4' 38.6 38.6 38.3 38.4 38.6 38.8 39.4 38.6 39.0 38.6 38.2
TABLE 6.2
FCV isolation from oropharyngeal swabs
7 0
Days 
after Infection
FCV isolated from cat number; 
2 3
-1
0
1
2
3
4
5
6
7
8 
9
10
11
12
14
16
19
22
26
34
45
51
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
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TABLE 6.3
Isolation of FCV or FHV from kittens given Katavac-CH vaccine
Days Isolation of virus from oropharynx of cats
after infection 5 6 7 8
0 
1
2
3
4 H
5 H . CH H
6 H H CH H
7 H H C H
8 CH E C H
9 V CH H
10 C C C C
11 C
12 C C
13 C O C C
14 C C C C
15 C C C C
16 C C C C
17 C C C C
18 C C C C
19 C C C C
20 C C C C
21 C C G C
22 C C C C
23 C C C C
24 G C
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TABLE 6.3 (Continued)
Isolation of FCV or FHV from kittens given Katavac-CH vaccine
Days Isolation of virus from oropharynx of cats
after infection 5 6 7 8
15 C C
26 C C
27 C
28 C
29 C
30 C
31 c C
32 C
33 C
34
\
C
35 C c C
36 C C
37 C C
38 C
39 C
40 C
41
42
43
44
45
C = FCV isolated
H = FHV isolated
Where no result is given, no virus was isolated.
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The results In Table 6.4 show that the titre of the excreted virus 
at 37®C was 1.4 x 10^ pfu/ml which was approximately the same as at 
3l®C (9.0 X 10^ pfu/ml). In contrast, the virus used to inoculate 
the cats had a titre of 5 x 10^ pfu/ml at 37*C which was 760-fold 
less than the titre at 3l*C (3.8 x 10^ pfu/ml).
The revertant virus clone which was studied was designated 
F CV-^R.
Revertant virus isolated from cell culture
The virus stock which had been used to inoculate the cats was 
passaged 3 times in FEA cell cultures and was then titrated at 31®C 
and 37*C without further cloning. The results are shown in Table 
6.4. It was found that the difference in titre of the resulting 
virus between 3l*C and 37®C was only 2.8 (1.3 x 10^ : 4.5 x 10^) 
compared to 760 for the original virus stock. This result 
indicated that viruses had been selected during the three passages 
of growth in vitro which were able to grow well at 37®C.
TABLE 6.4
Testing for revertant of FCV-ts to wild type
Dilution No . of plaques Titre of virus
Virus of virus per well (pfu /ml)
(logio) 31 ®C 37°C 31°C 37°C
FCV-ts -5 19, 19 0, 0 3.8 X 10^
-2 3, 2 5.0 X 102
Excreted -6 3, 4 4, 10 9.0 X 106 1.4 X 10^
Virus
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TABLE 6.5
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Revertant virus from cell culture
Temperature Dilution No. of Titre of virus
of virus plaques (pfu/ml)
arc 10-5 10, 3 1.3 X 10&
37 ®C 10-4 15, 30 4.5 X 1q5
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Discussion
In this Chapter the FCV-ts mutant which was given intranasally 
to the cats was found to grow for a period of 26 days in all 4 
cats. This compared with periods of 26-40 days for Katavac-CH FCV 
which was derived from an attenuated FCV (0, Jarrett, personal 
communication). Also Orr et a l . (1980) found that FCV was
recovered for up to 83 days following vaccination with Katavac CH,
The relatively long period during which FCV was recovered from 
the cats in the present experiment compared to temperature 
sensitive FHV in these previous experiments might be attributed to 
one of two main reasons. First the biology of FCV and FHV might be 
different. For example the difference in the length of time bf 
growth in the oropharynx might be an indication that the immune 
response of the cat to FHV is more efficient than that against 
FCV. A  second alternative reason might be that a revertant FCV 
emerged which was able to grow at 37®C and was therefore similar in 
its growth properties in vivo to the ’wild type’ FCV vaccine 
component in Katavac-CH.
When virus isolated 26 days after infection from one of the 
cats (cat 2) was tested, it was found to grow as well at 37®C as at 
31®C. Also virus passaged in vitro gave rise to similar viruses. 
The reason for the appearance of this virus might be that it was a 
real revertant. Revertants occur with high frequency in RNA virus 
mutants (Ramig, 1985). Reversion can occur in a number of ways. 
For example by a back mutation at the nucleotide of the original 
mutation, restoring the wild type nucleotide sequence (true 
reversion); or a second mutational event can occur at another site 
in the same gene which restores a frame shift mutation to the 
original correct reading frame (suppression). Mackenzie (1975) 
suggested that most reversions in foot-and-mouth disease virus ts 
mutants were the result of a second independent mutation in the 
same gene rather than true reversion since ^  revertants did not 
always show restoration of virulence.
GENERAL DISCUSSION
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An alternative reason for the appearance of a FCV which grew 
at the non-permissive temperature might be that the original mutant 
virus stock was contaminated with wild type virus carried through 
the cloning procedure. While it is not possible to completely 
exclude this possibility, it seems unlikely since the virus was 
plaque purified 3 times and was filtered between each cycle of 
cloning through a 0.22 ym filter to try to eliminate viral clumps. 
The difference in titre at 31°C and 37°C of the resulting virus was 
760. A much smaller difference might have been expected if a wild 
type virus had been carried through each cycle of cloning in a 
viral aggregate.
In an attempt to overcome the difficulties encountered with 
some previous live virus vaccines, the use of the mutant as a 
vaccine strain was investigated. This FCV-ts mutant was developed 
from attenuated virus vaccine to minimize the probable risk of 
pathogenic infection. However, FCV-ts was found in this study to 
revert to the wild type characteristic which was to grow as well at 
37°C as at 3l°C and the virus survived for a long period in cats. 
However, the virus did not appear to revert to virulence since no 
pathogenic effects were observed following infection. Studies 
which were done previously on the FCV virus in the Katavac vaccine 
showed that reversion to virulence of the vaccine viruses does not 
occur (Katavac-CH International Technical Manual). The present 
work indicates that mutants of FCV may not be more suitable as 
vaccines than wild type attenuated vaccines.
However, this property may not apply to all FCV mutants 
since in other RNA viruses mutants have been used as vaccines. 
For example Mills et al. (1971) found that a mutant of influenza 
virus was useful as a live, attentuated vaccine and recently Caplan 
et al. (1985) derived an attenuated strain of Rift Valley Fever 
virus after serial mutagenesis with 5-FU for use as a live virus 
vaccine. Their work suggests that it may be necessary to induce 
multiple mutations in the same gene of RNA viruses to minimise the 
risk of reversion to the wild type phenotype.
The aim of this study was to Isolate a ^s^ mutant of FCV and to 
Investigate its use as a vaccine similar to the ^2 FHV in existing 
vaccines and for genetic analysis of the virus.
A  ^s^ mutant was isolated from FCV-K which was an avirulent 
vaccine virus by treating infected cells with 5-FU in an attempt to 
increase the number of mutants. One mutant was isolated from 192 
clones after selection at 3l°C which is near the nasal passage 
temperature. It was not clear if this clone was a pre-existing 
mutant or whether 5-FU increased the proportion of mutants in the 
population as in vesicular stomatitis virus (Pringle, 1970). To 
confirm this would require experiments in which the proportion of 
mutants would be determined at different concentrations of the 
mutagen to find if increasing concentrations increased the 
proportion of mutants.
The FCV mutant was cloned by 3 cycles of plaque
purification and this virus was passed through a 0.22 ym filter at 
each stage in an attempt to reduce viral clumps which might have 
contained residual wild type virus- This process seemed to be 
successful in getting rid of the wild type virus since there was a
difference of 760 between the virus titre at 3 1 ®C and 37®C.
As expected the growth of the mutant was found to be prolonged 
at 3l*C compared to the wild type of FCV at 37®C. The eclipse 
phase lasted 10 hours and the maximum yield was at 24 hours after 
infection. However these yields were in general found to be low 
compared to those reported for wild type virus (Ormerod, 1979).
With lower titred virus stocks it was originally considered 
that it might be difficult to carry out one-step growth 
experiments. However, using immunofluorescence it was found that 
37% of the cells were infected by the mutant when l le
multiplicity of infection was about 1 compared to 28% of the wi _d
type FCV under conditions where a multiplicity of infection of up 
to 100 was used (Ormerod, 1979). It is not clear why the remaining 
cells resist the infection even at the high multiplicities of 
infection used by Ormerod (1979).
In temperature shift experiments the mutant virus was found 
not to be thermolabile over a period of 6 hours. Also adsorption 
to FEA cells was equally efficient at 3l*C and 37*C. However an 
early event appeared to be t^ since temperature shift to 37*C even 
2 hours after adsorption reduced the yield of virus dramatically.
The only FCV-specific protein identified for certain is the 
capsid protein with a molecular weight of 68,000 (Komolafe, 1978). 
These results might indicate that this protein was not thermolabile 
since the virus particle was stable at 37®C. This has been shown 
to correlate with the ^s^ lesion in some mutants in other viruses 
although the correlation is not absolute (Polatnick and Richmond, 
1980). Future work on the lesion should be to examine in detail 
protein synthesis in infected cells by pulse labelling with 
radiolabelled amino acids and analysing the labelled products by 
polyacrylamide gel electrophoresis (Komolafe, 1978). Protein 
synthesis in FCV-infected cells should be mainly virus-specific 
(Komolafe, 1978). Virus specificity could be further defined using 
radioimmune precipitation with anti-capsid protein antibodies.
However, other results suggested that the lesion might be in 
another gene, the RNA polymerase. No such enzymatic activity has 
been investigated in FCV-infected cells and a viral polymerase has 
not been identified. The results showed that RNA synthesis was 
reduced at the non-permissive temperature by a factor of 4. The 
simplest explanation of this finding is that viral RNA polymerase 
is ts. This could be investigated further using an assay for 
polymerase activity similar to that used for foot-and-mouth disease 
virus by Polatnick and Richmond (1980) to find if in vitro, as well 
as in vivo, RNA synthesis is ts.
An alternative explanation of these results is that FCV RNA is 
synthesised normally at the non-permissive temperature but is then 
degraded by ribonuclease because it is not protected by, for 
example, a ^  capsid protein. This has been suggested for mutants 
of foot-and-mouth disease virus by Polatnick and Richmond (1980).
Future experiment to investigate protein synthesis in FCV t^ 
infected cells as described above might also identify a 
polymerase. Although there is no antibody available which is 
specific for polymerase, the sera of convalescent cats should 
contain antibody to all virus-specific proteins, not only capsid 
protein as shown by Komolafe et al « (1980). Demonstration of a 
protein produced at 3l*C but not at 37*C might identify a potential 
polymerase molecule although it is quite likely that the enzyme 
might be synthesised at the non-permissive temperature but remain 
non-functional.
A  major aim of this work was to find if a FCV could be used 
as a vaccine against FCV infection of cats in the same way that a 
ts FHV has been used. The idea of the vaccine was that the viral 
mutant would grow in the nasopharynx but would not be invasive and 
would only survive a short time before being eliminated by the 
immune response. When kittens were inoculated with FCV-ts 
intranasally, the virus was subsequently isolated from the 
oropharynx over a period of 26 days. This result was unexpected 
since this period is similar to the 40 days during which the FCV in 
the original vaccine was found, but shorter than the 83 days found 
by Orr et a l . (1980). Therefore the lesion did not appear to 
influence the period during which the virus could grow in the upper 
respiratory tract.
One possible reason for this long period of growth was that 
the virus might have reverted and be able to grow again at 37°C. 
When tested, this was found to be the case since virus isolated 
from one of the kittens 26 days after infection was shown to grow 
at 37*C and when a clone was purified it was shown to grow as well 
at 37®C as at 31 ®C. This result suggested that a revertant had 
arisen during growth in the cat and was responsible for the 
prolonged growth of the virus in the oropharynx. A  similar 
situation was found in vitro when FCV-ts was passaged 3 times in 
FEA cells and the progeny was found to grow well at 37®C compared 
to the original ^  isolate. As discussed in Chapter 6, it was 
considered unlikely that this result was due to a carry-over of
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virus In clumps during the original cloning procedure and was more 
likely to be caused by a true revertant virus.
Therefore it was considered that this particular mutant of 
FCV would not be useful as a vaccine since because of reversion it 
showed no advantage over the parent vaccine virus. However, in 
future it might be useful to try to isolate other mutants and to 
test them in vitro for reversion before testing them in cats. In 
addition it would be preferable to try to obtain mutants with 
multiple t^ lesions in the same gene so that the chance of 
reversion was reduced.
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